Bio-Techne Expands Genetic Testing Through Partnership with Oxford Nanopore Technologies

Bio-Techne Strengthens Genetic Testing Capabilities Through Enhanced Collaboration with Oxford Nanopore Technologies

Bio-Techne Corporation, a prominent player in the life sciences sector, recently solidifies its partnership with Oxford Nanopore Technologies by broadening its commercial rights to develop a comprehensive range of genetic products. This expanded agreement, which extends their collaboration through 2032, follows the successful introduction of the AmplideX® Nanopore Carrier Plus Kit, launched in March 2025. The renewed partnership aims to streamline the development and commercialization of targeted enrichment sequencing kits designed specifically for the screening and diagnosis of heritable genetic disorders, addressing a critical need in the healthcare landscape.

The collaboration merges Bio-Techne's extensive diagnostic expertise with Oxford Nanopore's cutting-edge molecular sensing technology, positioning both companies to further advance genetic testing solutions. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, highlights the company's dedication to simplifying laboratory workflows and enhancing the depth of insights available to clinicians and researchers. This initiative not only aims to improve the efficiency of genetic testing but also strives to make these vital diagnostic tools more accessible to laboratories around the globe.

With Bio-Techne generating over $1.2 billion in net sales in fiscal year 2025 and employing around 3,100 individuals worldwide, the company showcases its strong foothold in the life sciences industry. The expanded partnership with Oxford Nanopore is set to accelerate innovation in diagnostics, laying a robust foundation for future product portfolios. This strategic alignment not only reflects Bio-Techne's commitment to enhancing genetic testing capabilities but also addresses the increasing demand for effective diagnostic solutions, ultimately benefiting healthcare providers and patients alike.

In addition to the latest partnership developments, Bio-Techne continues to encourage stakeholders to explore its diverse offerings through its website and social media channels. The company's ongoing focus on innovation and collaboration underscores its vital role in the evolution of genetic diagnostics and its responsiveness to the ever-growing needs of the life sciences sector. As the partnership progresses, the industry anticipates significant advancements that could redefine genetic testing methodologies.